Key takeaways:

Labcorp said its national network can ease burdens of access to testing for Alzheimer’s disease.

Blood-based biomarker tests are intended to support the diagnostic process, not replace clinical judgment.

Access to rapidly developing diagnostic technology such as blood-based biomarkers for early detection and subsequent treatment of Alzheimer’s disease is an ongoing issue in the United States.

The blood-based Lumipulse test from Fujirebio Diagnostics measures the ratio of pTau-217 to beta amyloid 42, indicating the likelihood of amyloid pathology. It has demonstrated a positive predictive value of 92% and a negative predictive value of 97%.

Labcorp plans to relieve access issues to rapid biomarker testing in Alzheimer's disease by wider distribution of the blood-based Lu

See Full Page